Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Biomarkers in Alzheimer's disease drug development

Nature Medicine volume 16, pages 1218–1222 (2010)Cite this article

Subjects

Abstract

Biomarkers may be of great value in Alzheimer's disease drug development to select the most optimal drug candidates for large and expensive phase 3 clinical trials. Biomarkers will also be important to provide evidence that a drug affects the underlying pathophysiology of the disease, which, together with a beneficial effect on the clinical course, will be essential for labeling the drug as having a disease-modifying effect.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Flow chart for hypothetical use of theragnostic biomarkers in Aβ-targeting clinical trials.

References

  1. Blennow, K., de Leon, M.J. & Zetterberg, H. Lancet 368, 387–403 (2006).

    Article  CAS  Google Scholar 

  2. Hardy, J. & Selkoe, D.J. Science 297, 353–356 (2002).

    Article  CAS  Google Scholar 

  3. Mangialasche, F. et al. Lancet Neurol. 9, 702–716 (2010).

    Article  CAS  Google Scholar 

  4. Holmes, C. et al. Lancet 372, 216–223 (2008).

    Article  CAS  Google Scholar 

  5. Garcia-Alloza, M. et al. Mol. Neurodegener. 4, 19 (2009).

    Article  Google Scholar 

  6. DeCarli, C. Lancet Neurol. 2, 15–21 (2003).

    Article  Google Scholar 

  7. Petersen, R.C. et al. N. Engl. J. Med. 352, 2379–2388 (2005).

    Article  CAS  Google Scholar 

  8. Hansson, O. et al. Lancet Neurol. 5, 228–234 (2006).

    Article  CAS  Google Scholar 

  9. Shaw, L.M. et al. Ann. Neurol. 65, 403–413 (2009).

    Article  CAS  Google Scholar 

  10. Visser, P.J. et al. Lancet Neurol. 8, 619–627 (2009).

    Article  Google Scholar 

  11. Mattsson, N. et al. J. Am. Med. Assoc. 302, 385–393 (2009).

    Article  CAS  Google Scholar 

  12. Frisoni, G.B., Fox, N.C., Jack, C.R. Jr., Scheltens, P. & Thompson, P.M. Nat. Rev. Neurol. 6, 67–77 (2010).

    Article  Google Scholar 

  13. Nordberg, A., Rinne, J.O., Kadir, A. & Langstrom, B. Nat. Rev. Neurol. 6, 78–87 (2010).

    Article  CAS  Google Scholar 

  14. Nelson, P.T., Kukull, W.A. & Frosch, M.P. J. Neuropathol. Exp. Neurol. 69, 449–454 (2010).

    Article  Google Scholar 

  15. Kotzbauer, P.T., Trojanowsk, J.Q. & Lee, V.M. J. Mol. Neurosci. 17, 225–232 (2001).

    Article  CAS  Google Scholar 

  16. Schneider, J.A., Arvanitakis, Z., Leurgans, S.E. & Bennett, D.A. Ann. Neurol. 66, 200–208 (2009).

    Article  Google Scholar 

  17. Rinne, J.O. et al. Lancet Neurol. 9, 363–372 (2010).

    Article  CAS  Google Scholar 

  18. Eriksen, J.L. et al. J. Clin. Invest. 112, 440–449 (2003).

    Article  CAS  Google Scholar 

  19. Galasko, D.R. et al. Alzheimer Dis. Assoc. Disord. 21, 292–299 (2007).

    Article  CAS  Google Scholar 

  20. Wilcock, G.K. et al. Lancet Neurol. 7, 483–493 (2008).

    Article  CAS  Google Scholar 

  21. Green, R.C. et al. J. Am. Med. Assoc. 302, 2557–2564 (2009).

    Article  CAS  Google Scholar 

  22. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Nat. Rev. Neurol. 6, 131–144 (2010).

    Article  CAS  Google Scholar 

  23. Bateman, R.J. et al. Ann. Neurol. 66, 48–54 (2009).

    Article  CAS  Google Scholar 

  24. Portelius, E. et al. Alzheimers. Res. Ther. 2, 7 (2010).

    Article  Google Scholar 

  25. Blennow, K. et al. Neurosci. Lett. 419, 18–22 (2007).

    Article  CAS  Google Scholar 

  26. Zetterberg, H. et al. J. Alzheimers Dis. 12, 255–260 (2007).

    Article  CAS  Google Scholar 

  27. Chen, X., Magnotta, V.A., Duff, K., Boles Ponto, L.L. & Schultz, S.K. J. Neuropsychiatry Clin. Neurosci. 18, 178–185 (2006).

    Article  CAS  Google Scholar 

  28. Tune, L. et al. Am. J. Geriatr. Psychiatry 11, 169–177 (2003).

    Article  Google Scholar 

  29. Krishnan, K.R. et al. Am. J. Psychiatry 160, 2003–2011 (2003).

    Article  Google Scholar 

  30. Hashimoto, M. et al. Am. J. Psychiatry 162, 676–682 (2005).

    Article  Google Scholar 

  31. Fagan, A.M. et al. Ann. Neurol. 59, 512–519 (2006).

    Article  CAS  Google Scholar 

  32. Degerman Gunnarsson, M. et al. Dement. Geriatr. Cogn. Disord. 29, 204–212 (2010).

    Article  CAS  Google Scholar 

  33. Hampel, H. et al. Nat. Rev. Drug Discov. 9, 560–574 (2010).

    Article  CAS  Google Scholar 

  34. Davidsson, P. & Blennow, K. Int. Pychogeriatr. 10, 11–23 (1998).

    Article  CAS  Google Scholar 

  35. Davidsson, P., Puchades, M. & Blennow, K. Electrophoresis 20, 431–437 (1999).

    Article  CAS  Google Scholar 

  36. Walsh, D.M. & Selkoe, D.J. J. Neurochem. 101, 1172–1184 (2007).

    Article  CAS  Google Scholar 

  37. Fukumoto, H. et al. FASEB J. published online, 10.1096/fj.09-150359 (25 March 2010).

  38. Portelius, E. et al. Neurobiol. Aging published online, 10.1016/j.neurobiolaging.2009.06.002 (14 July 2009).

  39. Portelius, E. et al. Neurodegener. Dis. 6, 258–262 (2009).

    Article  CAS  Google Scholar 

  40. Cook, J.J. et al. J. Neurosci. 30, 6743–6750 (2010).

    Article  CAS  Google Scholar 

  41. Portelius, E. et al. J. Alzheimers Dis. published online, 10.3233/JAD-2010-100573 (15 July 2010).

  42. Fleisher, A.S. et al. Arch. Neurol. 65, 1031–1038 (2008).

    Article  Google Scholar 

  43. Lannfelt, L. et al. Lancet Neurol. 7, 779–786 (2008).

    Article  CAS  Google Scholar 

  44. Gilman, S. et al. Neurology 64, 1553–1562 (2005).

    Article  CAS  Google Scholar 

  45. Fox, N.C. et al. Neurology 64, 1563–1572 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Neurochemistry, Kaj Blennow is at the Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.,

    Kaj Blennow

Authors
  1. Kaj Blennow
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kaj Blennow.

Ethics declarations

Competing interests

The author declares competing financial interests: details accompany the full-text HTML version of the paper at http://www.nature.com/naturemedicine/.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blennow, K. Biomarkers in Alzheimer's disease drug development. Nat Med 16, 1218–1222 (2010). https://doi.org/10.1038/nm.2221

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2221

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research